Literature DB >> 26603971

Differences in baseline factors and survival between normocapnia, compensated respiratory acidosis and decompensated respiratory acidosis in COPD exacerbation: A pilot study.

Chung-Tat Lun1, Miranda S N Tsui1, Suet-Lai Cheng1, Veronica L Chan1, Wah-Shing Leung1, Alice P S Cheung1, Chung-Ming Chu1.   

Abstract

BACKGROUND AND
OBJECTIVE: Patients with chronic obstructive pulmonary disease (COPD) experiencing acute exacerbation (AE-COPD) with decompensated respiratory acidosis are known to have poor outcomes in terms of recurrent respiratory failure and death. However, the outcomes of AE-COPD patients with compensated respiratory acidosis are not known.
METHODS: We performed a 1-year prospective, single-centre, cohort study in patients surviving the index admission for AE-COPD to compare baseline factors between groups with normocapnia, compensated respiratory acidosis and decompensated respiratory acidosis. Survival analysis was done to examine time to readmissions, life-threatening events and death.
RESULTS: A total of 250 patients fulfilling the inclusion and exclusion criteria were recruited and 245 patients were analysed. Compared with normocapnia, both compensated and decompensated respiratory acidosis are associated with lower FEV1 % (P < 0.001), higher GOLD stage (P = 0.003, <0.001) and higher BODE index (P = 0.038, 0.001) and a shorter time to life-threatening events (P < 0.001). Comparing compensated and decompensated respiratory acidosis, there was no difference in FEV1 (% predicted) (P = 0.15), GOLD stage (P = 0.091), BODE index (P = 0.158) or time to life-threatening events (P = 0.301). High PaCO2 level (P = 0.002) and previous use of non-invasive ventilation (NIV) in acute setting (P < 0.001) are predictive factors of future life-threatening events by multivariate analysis.
CONCLUSIONS: Compared with normocapnia, both compensated and decompensated respiratory acidosis are associated with poorer lung function and higher risk of future life-threatening events. High PaCO2 level and past history of NIV use in acute settings were predictive factors for future life-threatening events. Compensated respiratory acidosis warrants special attention and optimization of medical therapy as it poses risk of life-threatening events.
© 2015 Asian Pacific Society of Respirology.

Entities:  

Keywords:  chronic obstructive pulmonary disease; compensated respiratory acidosis; decompensated respiratory acidosis; life-threatening event; survival

Mesh:

Year:  2015        PMID: 26603971     DOI: 10.1111/resp.12652

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  4 in total

1.  One-year and long-term mortality in patients hospitalized for chronic obstructive pulmonary disease.

Authors:  María-Teresa García-Sanz; Juan-Carlos Cánive-Gómez; Laura Senín-Rial; Jorge Aboal-Viñas; Alejandra Barreiro-García; Eva López-Val; Francisco-Javier González-Barcala
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Respiratory parameters predict poor outcome in COPD patients, category GOLD 2017 B.

Authors:  Kristian Brat; Marek Plutinsky; Karel Hejduk; Michal Svoboda; Patrice Popelkova; Jaromir Zatloukal; Eva Volakova; Miroslava Fecaninova; Lucie Heribanova; Vladimir Koblizek
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-03-26

3.  Comorbidities, mortality, and management of chronic obstructive pulmonary disease patients who required admissions to public hospitals in Hong Kong - computerized data collection and analysis.

Authors:  Hok Sum Chan; Fanny Wai San Ko; Johnny Wai Man Chan; Loletta Kit Ying So; David Chi Leung Lam; Veronica Lee Chan; Cheuk Yin Tam; Wai Cho Yu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-06-13

4.  Comparative analysis of medical expenditure with nebulized budesonide versus systemic corticosteroids in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease in China.

Authors:  Jing Zhang; Wanzhen Yao; Xuedan You; Tianyi Liu; Yuantao Liu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.